25 resultater (0,25284 sekunder)

Mærke

Butik

Pris (EUR)

Nulstil filter

Produkter
Fra
Butikker

Race and the Genetic Revolution - - Bog - Columbia University Press - Plusbog.dk

Building a Meal - Herve This - Bog - Columbia University Press - Plusbog.dk

Encountering Religion - Tyler T. Roberts - Bog - Columbia University Press - Plusbog.dk

Building a Meal - Herve This - Bog - Columbia University Press - Plusbog.dk

The Kitchen as Laboratory - - Bog - Columbia University Press - Plusbog.dk

The Kitchen as Laboratory - - Bog - Columbia University Press - Plusbog.dk

The Best Business Writing 2012 - - Bog - Columbia University Press - Plusbog.dk

The Best Business Writing 2012 - - Bog - Columbia University Press - Plusbog.dk

An anthology Malcolm Gladwell has called "riveting and indispensable," The Best Business Writing is a far-ranging survey of business's dynamic relationship with politics, culture, and life. This year's selections include John Markoff (New York Times) on innovations in robot technology and the decline of the factory worker; Evgeny Morozov (New Republic) on the questionable value of the popular TED conference series and the idea industry behind it; Paul Kiel (ProPublica) on the ripple effects of the ongoing foreclosure crisis; and the infamous op-ed by Greg Smith, published in the New York Times, announcing his break with Goldman Sachs over its trading practices and corrupt corporate ethos. Jessica Pressler (New York) delves into the personal and professional rivalry between former spouses and fashion competitors Tory and Christopher Burch. Peter Whoriskey (Washington Post) exposes the human cost of promoting pharmaceuticals for off-label uses. Charles Duhigg and David Barboza (New York Times) investigate Apple's unethical labor practices in China. Max Abelson (Bloomberg) reports on Wall Street's amusing reaction to the diminishing annual bonus. Mina Kimes (Fortune) recounts the grisly story of a company's illegal testing-and misuse-of a medical device for profit, and Jeff Tietz (Rolling Stone) composes one of the most poignant and comprehensive portraits of the financial crisis's dissolution of the American middle class.

DKK 174.00
1

The Best Business Writing 2013 - - Bog - Columbia University Press - Plusbog.dk

The Best Business Writing 2013 - - Bog - Columbia University Press - Plusbog.dk

An anthology Malcolm Gladwell has called "riveting and indispensable," The Best Business Writing is a far-ranging survey of business's dynamic relationship with politics, culture, and life. This year's selections include John Markoff (New York Times) on innovations in robot technology and the decline of the factory worker; Evgeny Morozov (New Republic) on the questionable value of the popular TED conference series and the idea industry behind it; Paul Kiel (ProPublica) on the ripple effects of the ongoing foreclosure crisis; and the infamous op-ed by Greg Smith, published in the New York Times, announcing his break with Goldman Sachs over its trading practices and corrupt corporate ethos. Jessica Pressler (New York) delves into the personal and professional rivalry between Tory and Christopher Burch, former spouses now competing to dominate the fashion world. Peter Whoriskey (Washington Post) exposes the human cost of promoting pharmaceuticals off-label. Charles Duhigg and David Barboza (New York Times) investigate Apple's unethical labor practices in China. Max Abelson (Bloomberg) reports on Wall Street's amusing reaction to the diminishing annual bonus. Mina Kimes (Fortune) recounts the grisly story of a company's illegal testing-and misuse-of a medical device for profit, and Jeff Tietz (Rolling Stone) composes one of the most poignant and comprehensive portraits of the financial crisis's dissolution of the American middle class.

DKK 180.00
1

The Quest for the Cure - Brent Stockwell - Bog - Columbia University Press - Plusbog.dk

The Quest for the Cure - Brent Stockwell - Bog - Columbia University Press - Plusbog.dk

After more than fifty years of blockbuster drug development, skeptics are beginning to fear we are reaching the end of drug discovery to combat major diseases. In this engaging book, Brent R. Stockwell, a leading researcher in the exciting new science of chemical biology, describes this dilemma and the powerful techniques that may bring drug research into the twenty-first century. Filled with absorbing stories of breakthroughs, this book begins with the scientific achievements of the twentieth century that led to today's drug innovations. We learn how the invention of mustard gas in World War I led to early anti-cancer agents and how the efforts to decode the human genome might lead to new approaches in drug design. Stockwell then turns to the seemingly incurable diseases we face today, such as Alzheimer's, many cancers, and others with no truly effective medicines, and details the cellular and molecular barriers thwarting scientists equipped with only the tools of traditional pharmaceutical research. Scientists such as Stockwell are now developing methods to combat these complexities--technologies for constructing and testing millions of drug candidates, sophisticated computational modeling, and entirely new classes of drug molecules--all with an eye toward solving the most profound mysteries of living systems and finding cures for intractable diseases. If successful, these methods will unlock a vast terrain of untapped drug targets that could lead to a bounty of breakthrough medicines. Offering a rare, behind-the-scenes look at this cutting-edge research, The Quest for the Cure tells a thrilling story of science, persistence, and the quest to develop a new generation of cures.

DKK 265.00
1

The Quest for the Cure - Brent Stockwell - Bog - Columbia University Press - Plusbog.dk

The Quest for the Cure - Brent Stockwell - Bog - Columbia University Press - Plusbog.dk

After more than fifty years of blockbuster drug development, skeptics are beginning to fear we are reaching the end of drug discovery to combat major diseases. In this engaging book, Brent R. Stockwell, a leading researcher in the exciting new science of chemical biology, describes this dilemma and the powerful techniques that may bring drug research into the twenty-first century. Filled with absorbing stories of breakthroughs, this book begins with the scientific achievements of the twentieth century that led to today's drug innovations. We learn how the invention of mustard gas in World War I led to early anti-cancer agents and how the efforts to decode the human genome might lead to new approaches in drug design. Stockwell then turns to the seemingly incurable diseases we face today, such as Alzheimer's, many cancers, and others with no truly effective medicines, and details the cellular and molecular barriers thwarting scientists equipped with only the tools of traditional pharmaceutical research. Scientists such as Stockwell are now developing methods to combat these complexities--technologies for constructing and testing millions of drug candidates, sophisticated computational modeling, and entirely new classes of drug molecules--all with an eye toward solving the most profound mysteries of living systems and finding cures for intractable diseases. If successful, these methods will unlock a vast terrain of untapped drug targets that could lead to a bounty of breakthrough medicines. Offering a rare, behind-the-scenes look at this cutting-edge research, The Quest for the Cure tells a thrilling story of science, persistence, and the quest to develop a new generation of cures.

DKK 228.00
1

Me Medicine vs. We Medicine - Donna Dickenson - Bog - Columbia University Press - Plusbog.dk

Me Medicine vs. We Medicine - Donna Dickenson - Bog - Columbia University Press - Plusbog.dk

Personalized healthcare-or what the award-winning author Donna Dickenson calls "Me Medicine"-is radically transforming our longstanding "one-size-fits-all" model. Technologies such as direct-to-consumer genetic testing, pharmacogenetically developed therapies in cancer care, private umbilical cord blood banking, and neurocognitive enhancement claim to cater to an individual's specific biological character, and, in some cases, these technologies have shown powerful potential. Yet in others they have produced negligible or even negative results. Whatever is behind the rise of Me Medicine, it isn't just science. So why is Me Medicine rapidly edging out We Medicine, and how has our commitment to our collective health suffered as a result? In her cogent, provocative analysis, Dickenson examines the economic and political factors fueling the Me Medicine phenomenon and explores how, over time, this paradigm shift in how we approach our health might damage our individual and collective well-being. Historically, the measures of "We Medicine," such as vaccination and investment in public-health infrastructure, have radically extended our life spans, and Dickenson argues we've lost sight of that truth in our enthusiasm for "Me Medicine." Dickenson explores how personalized medicine illustrates capitalism's protean capacity for creating new products and markets where none existed before-and how this, rather than scientific plausibility, goes a long way toward explaining private umbilical cord blood banks and retail genetics. Drawing on the latest findings from leading scientists, social scientists, and political analysts, she critically examines four possible hypotheses driving our Me Medicine moment: a growing sense of threat; a wave of patient narcissism; corporate interests driving new niche markets; and the dominance of personal choice as a cultural value. She concludes with insights from political theory that emphasize a conception of the commons and the steps we can take to restore its value to modern biotechnology.

DKK 252.00
1

Me Medicine vs. We Medicine - Donna Dickenson - Bog - Columbia University Press - Plusbog.dk

Me Medicine vs. We Medicine - Donna Dickenson - Bog - Columbia University Press - Plusbog.dk

Personalized healthcare-or what the award-winning author Donna Dickenson calls "Me Medicine"-is radically transforming our longstanding "one-size-fits-all" model. Technologies such as direct-to-consumer genetic testing, pharmacogenetically developed therapies in cancer care, private umbilical cord blood banking, and neurocognitive enhancement claim to cater to an individual's specific biological character, and, in some cases, these technologies have shown powerful potential. Yet in others they have produced negligible or even negative results. Whatever is behind the rise of Me Medicine, it isn't just science. So why is Me Medicine rapidly edging out We Medicine, and how has our commitment to our collective health suffered as a result? In her cogent, provocative analysis, Dickenson examines the economic and political factors fueling the Me Medicine phenomenon and explores how, over time, this paradigm shift in how we approach our health might damage our individual and collective well-being. Historically, the measures of "We Medicine," such as vaccination and investment in public-health infrastructure, have radically extended our life spans, and Dickenson argues we've lost sight of that truth in our enthusiasm for "Me Medicine." Dickenson explores how personalized medicine illustrates capitalism's protean capacity for creating new products and markets where none existed before-and how this, rather than scientific plausibility, goes a long way toward explaining private umbilical cord blood banks and retail genetics. Drawing on the latest findings from leading scientists, social scientists, and political analysts, she critically examines four possible hypotheses driving our Me Medicine moment: a growing sense of threat; a wave of patient narcissism; corporate interests driving new niche markets; and the dominance of personal choice as a cultural value. She concludes with insights from political theory that emphasize a conception of the commons and the steps we can take to restore its value to modern biotechnology.

DKK 212.00
1